SCHEMBL4527192

SCHEMBL4527192

COc1ccc(C(=O)Nc2cc(C(=O)Nc3ccncc3)ccc2C(C)N)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
KMT2A Q03164 5/20 0.60
RAB9A P51151 5/20 0.60
NPC1 O15118 4/20 0.60
MEN1 O00255 3/20 0.60
POLB P06746 2/20 0.60
ROCK2 O75116 3/20 0.57
ROCK1 Q13464 2/20 0.57
LMNA P02545 2/20 0.53
ALDH1A1 P00352 2/20 0.53
PKM P14618 1/20 0.53
TP53 P04637 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.51
NAMPT P43490 1/20 0.51
PSMD14 O00487 1/20 0.51
MAPT P10636 1/20 0.50
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4511323 0.99 KDM4E (0.63) KDM4EKMT2ARAB9ANPC1MEN1
SCHEMBL4517784 0.90 KMT2A (0.64) KDM4EKMT2ARAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL4508660 0.89 KMT2A (0.63) KDM4EKMT2ARAB9ANPC1MEN1
SCHEMBL4517023 0.87 ROCK2 (0.61) KDM4EKMT2ARAB9ANPC1MEN1
SCHEMBL4525552 0.86 KMT2A (0.63) KDM4EKMT2AMEN1ROCK2ROCK1
Hydrochloric Acid SCHEMBL4511190 0.86 ROCK2 (0.62) KDM4EKMT2ARAB9ANPC1MEN1
SCHEMBL4512176 0.86 ROCK2 (0.77) KDM4EKMT2ARAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL4517367 0.85 KMT2A (0.61) KDM4EKMT2AMEN1ROCK2ROCK1
Hydrochloric Acid SCHEMBL4506859 0.85 ROCK2 (0.75) KDM4EKMT2ARAB9ANPC1MEN1
SCHEMBL6560211 0.82 KMT2A (0.70) KDM4EKMT2ARAB9AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US claimed
EP-1934181-A2 KINASE INHIBITORS Devgen NV (BE) 2008-06-25 EP claimed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO claimed
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US disclosed
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233960-A1 Kinase Inhibitors ROCK1, MAP3K1, MAP3K11 KDM4E 4294/4885KMT2A 3194/4885RAB9A 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.